About Clade TX
Clade TX is a Healthcare company based in Cambridge (United States) founded in 2020 by Leandro Vetcher, and was acquired by Century Therapeutics in April 2024. Stem cell-derived therapies for cancer are developed using pluripotent cells. Clade TX has raised $87 million across 1 funding round from investors including Century Therapeutics, Syncona and Bristol-Myers Squibb. The company has 13 employees. Clade TX has completed 1 acquisition, including Gadeta. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Diversified. Its legal entity is CLADE THERAPEUTICS, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Clade was founded in 2020 and is based in Cambridge, United States. Platform technologies are utilized by the company to create therapies derived from human pluripotent stem cells and their derivatives. These therapies focus on cell transplantation for cancer treatment within the biotechnology sector. Operations emphasize the advancement of stem cell-based solutions for oncology applications.
- Headquarters Cambridge, United States
- Employees 13
- Founders Leandro Vetcher
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cladetx.com
- Social LinkedIn
- Acquired by Century Therapeutics (Apr 2024)
- Legal Name Clade Therapeutics, Inc
- Total Equity Funding$87M (USD)
in 1 rounds
- Latest Funding Round$87M (USD), Series A
Nov 2021
- InvestorsCentury Therapeutics
& 4 more
- Employee Count13
- Investments & Acquisitions
- Acquired byCentury Therapeutics
(Apr 2024)
Funding Insights of Clade TX
Clade TX has successfully raised a total of $87M through 1 strategic funding round. The most recent funding activity was a Series A round of $87 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87M
- Total Rounds 1
- Last Round Series A — $87M
- First Round $87M
(Nov 2021)
- Investors Count 4
All 1 funding rounds of Clade TX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $87M | Series A | – | Syncona |
5 investors in total: 5 institutional.
Investors in Clade TX
Clade TX has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Century Therapeutics, Syncona and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
| emersoncollective.com | ||||
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Developer of adult stem cells to develop therapies for cancer | 2018 | centurytx.com | Philadelphia, United States |
Investor details for Clade TX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Clade TX
15 people are tracked at Clade TX (3 in leadership, 9 in board & advisors, 3 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Leandro Vetcher | Co-Founder | Leadership |
Chad Cowan | CEO & Co-Founder | Leadership |
Grant Welstead | Executive Director, Disease Biology | Leadership |
Chris Sturgeon | Scientific Co-founder | Board & advisors |
Gustavo Mostoslavsky | Scientific Co-Founder | Board & advisors |
Jonathan M. Gerber | Advisor | Board & advisors |
Jermone Ritz | Advisor | Board & advisors |
Derrick Rossi | Advisor | Board & advisors |
Daniel Vasella | Chairman | Board & advisors |
Martin Murphy | Director | Board & advisors |
Neil White | Director | Board & advisors |
Deepta Bhattacharya | Scientific Co-Founder | Board & advisors |
Melissa Chin | Principal Research Associate | Team |
Dar Heinze | Senior Scientist | Team |
Kristen Dettloff | Senior Research Associate, Cell Differentiation | Team |
Complete people profiles for Clade TX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Clade TX
Clade TX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Gadeta.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
T Cell based cancer therapies based on gamma delta (γδ) T cell receptors | gadeta.nl | Utrecht, Netherlands | 2015 | Oct 2023 | •••• |
Complete acquisition details for Clade TX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Clade TX
4 dated milestones of Clade TX across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Clade TX is founded.
- Funding First funding round of $87.0M.
- Acquisition Acquires Gadeta.
- Exit Acquired by Century Therapeutics.
Competitors of Clade TX
Clade TX has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Clade TX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Clade TX (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Clade Tx
Complete news archive for Clade TX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clade TX
Clade TX was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Clade TX is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Clade TX is a funded company, having raised a total of $87M across 1 funding round to date. The company's 1st funding round was a Series A of $87M, raised on Nov 2021.
Clade TX has 13 employees.
Clade was founded in 2020 and is based in Cambridge, United States. Platform technologies are utilized by the company to create therapies derived from human pluripotent stem cells and their derivatives. These therapies focus on cell transplantation for cancer treatment within the biotechnology sector. Operations emphasize the advancement of stem cell-based solutions for oncology applications.
Clade TX has made 1 acquisition, including Gadeta.
Clade TX has 5 investors. Key investors include Century Therapeutics, Syncona, Bristol-Myers Squibb, LifeSci Venture Partners, and Emerson Collective.
Clade TX operates through Clade Therapeutics, Inc.
Yes. Clade TX was acquired by Century Therapeutics in April 2024.